PEPTIDE
Verified Peptide ReviewLast reviewed: 26 March 2026

Compound Profile · GH Secretagogue

Ipamorelin

Ipamorelin is a selective GH secretagogue often paired with CJC-1295 in research. It is not approved for human use.

LegalResearch onlyEvidenceModerateHuman useNot approved
7.4/ 10

Peptide Score

Evidence

8.0

Safety

8.8

Regulatory

8.6

Transparency

8.6

Quick verdict

Cleanest GH secretagogue profile in research — minimal cortisol/prolactin elevation. But not approved for human use anywhere; research-context only.

Reality check

What this isn't

  • Not approved for human use in any jurisdiction
  • WADA prohibited (S2 — peptide hormones)
  • Most commonly studied in combination with CJC-1295, not alone
  • Long-term effects on GH axis not characterized in humans
  • Selective profile advantage not yet validated vs. real-world superiority
  • Injectable peptide; subcutaneous administration
  • Educational research review only — not medical advice

Results snapshot

Selective GH pulse

GH release profile (no cortisol elevation)

8

Weeks

Preclinical

Trial phase

What this means: Demonstrated selective GH release in human studies without significant cortisol or prolactin elevation, distinguishing it from older secretagogues. Frequently paired with CJC-1295; effectiveness as monotherapy less researched.

Reported timeline

What participants experienced

  1. 1

    Administration

    GH secretion pulse initiated

  2. 2

    Peak effect

    GH elevation without cortisol surge

  3. 3

    Combined use

    Often paired with GHRH analogs for synergistic effect

  4. 4

    Research context

    Studied for recovery and body composition; never advanced to approval pathway

Deep dive

Full Ipamorelin review

A pentapeptide GH secretagogue acting on the ghrelin/GHS-R.

Selective for GH release with limited cortisol/prolactin elevation in research.

CompareResearch-gradeSafety